Table 1. Summary of clinical parameters of AML patients used in this study.

Patient ID	FAB	% CD34	Karyotype	FLT3-ITD	Responses to cytokines
2003-119	M0	80	N	+	c.a. TPO, IL-3, GM-CSF
2005-258	M0	73	-5q; +6	ND	G-CSF, IL-3
2006-014	M1	19	N	+	TPO, IL-3 GM-CSF
2005-016	M1	65	N	−	c.a., G-CSF
2004-168	M2	21	del (9) (q12;q22)	+	c.a., TPO, IL-3
2007-046	M2	20	N	+	TPO, G-CSF, IL-3
2003-152	M4	72	Inv (16)	−	TPO, G-CSF, IL-3
2005-289	M5	95	N	−	IL-3, GM-CSF, G-CSF
2003-114	M5	27	t(11;20)	+	c.a., G-CSF, GM-CSF
2007-272	M7	36	Complex	−	c.a. TPO, IL-3

AML cells derived from peripheral blood (PB); Percentage of CD34⁺ (% CD34) in the total AML mononuclear cell fraction; FAB, French-American-British classifications; FLT3-ITD (internal tandem duplication) was present (+) or absent (−) in the AML cells; ND, not determined; N, normal; c.a. constitutive activation of STAT5.